About Cancer

If cancer has been a chapter in your life or in your family’s history; we, as your personal physicians, will walk this journey with you.

Your 1to1 doctor works in partnership with your oncologist to deliver best outcomes and limit complications before, during, and after oncology care.

CORONAVIRUS DISEASE 2019 (COVID-19)

Cancer patients are at high risk of serious illness because their immune systems are often weakened by cancer and its treatments. Most people who were treated for cancer in the past (especially if it was years ago) are likely to have normal immune function, but each person is different. It’s important that all cancer patients and survivors, whether currently in treatment or not, talk with a doctor.¹

Based on most current data, 1 of every 10 patients who had cancer that was either active or in remission died within 30 days of their coronavirus diagnosis.² If you have cancer, you are almost 4 times the risk of requiring mechanical ventilation or ICU admission, and 10 times the risk of dying from COVID-19 compared to the general population.^2,3,4 Additionally, limited resources in outpatient settings, including access to medical specialties, has hindered the routine care of cancer patients.

As a 1to1 patient, you are not bound to lack of resources. Your 1to1 physician and all possible resources are and will always be available and at your disposal.

The most common symptoms of COVID-19, which may appear 2-14 days after exposure, are: fever of at least 100.4°F (38°C), cough, shortness of breath, chills, muscle aches and pains, sore throat, loss of smell or taste, and gastrointestinal symptoms. Some people with COVID-19 might have signs or symptoms of blood clots such as bluish toes (also referred to as “COVID toes”), swelling of the lower legs, chest pain, or stroke symptoms (slurred speech, weakness or numbness of an arm or leg). Children, in particular, might have fewer symptoms. However, there have been recent reports of children with symptoms such as fever and rash.

If you or your loved ones have been at risk of exposure or experience any of these symptoms, please call your 1to1 concierge doctor to his personal cellphone right away. We will be able to help you.

Tremendous efforts are underway for vaccine development targeting COVID-19.⁶ However, it may be difficult to illicit a strong immune response in immunocompromised cancer patients.

General public health recommendations to be cautious about:
Earlier in the U.S. outbreak, the CDC and Surgeon General Jerome Adams told everyday Americans to stop buying masks, despite multiple studies demonstrating the airborne capabilities of transmission of the coronavirus.^7,8,9

The American Red Cross stated there is no evidence that this new coronavirus can be transmitted through a blood transfusion;10 but an earlier study done in China isolated the virus in different human fluids, including blood.¹¹

Please understand that measures taken
for public health are not individualized care

COVID-19 VACCINES

There are, at least, a dozen COVID vaccines under investigation in late stage clinical trials. Currently, five different vaccine platforms are being used: inactivated, non-replicating viral vector, protein subunit, DNA, and mRNA. The latter platform is a new technology, and has recently received emergency authorization for use in the United States. Note that this does not mean FDA approval, which requires a more stringent process.

Please talk to your 1to1 physician
and ask about which vaccine is best for you

FAMILY HISTORY

Family history of cancer is one of the biggest predictors of cancer risk. Talk to your 1to1 doctor if you or your family have a history of:

Cancer Types

If you would like further information, please contact us at 1.469.708.9997 or info@1to1.md
 

CONTACT US

1 American Cancer Society -Common Questions About the New Coronavirus Outbreak https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html

2 Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; This was the first study to evaluate cancer patients being at a higher risk of serious illnesses from COVID-19, and rather extra precaution is very much advised for this patient population.

3 Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; Highlights initial stages of COVID-19 was managed in China, and further management steps were utilized globally.

4 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA2020; available from: 10.1001/jama.2020.4683.

5 Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020; Highlights briefly important aspects of cancer care within the United States.

6 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9

7 CDC and WHO offer conflicting advice on masks. An expert tells us why. https://www.msn.com/en-us/health/medical/cdc-and-who-offer-conflicting-advice-on-masks-an-expert-tells-us-why/ar-BB14Mys2

8 Olsen SJ, Chang HL, Cheung TY, Tang AF, Fisk TL, Ooi SP, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med. 2003;349:2416–2422. doi: 10.1056/NEJMoa031349.

9 Yu IT, Li Y, Wong TW, Tam W, Chan AT, Lee JH, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350:1731–1739. doi: 10.1056/NEJMoa032867.

10 American Cancer Society -Common Questions About the New Coronavirus Outbreak https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html

11 Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–389. doi: 10.1080/22221751.2020.1729071.